No systematic review of evidence for recommending blood spot test
Reviews do not assess evidence on the benefits and harms of screening
Many national policy reviews of screening for rare conditions using the newborn blood spot test do not assess evidence on the benefits and harms of screening.
Researchers assessed whether international differences in recommendations of whether to screen for rare diseases using the new-born blood spot test may be explained by use of systematic review methods.
Across the world the conditions screened for by the new-born blood spot test differ. The number ranges from five to 60 on screening panels.
Reviewers analysed 93 reports that included 104 conditions from 14 from North America, Europe, Asia and Australasia.
The reports assessed a total of 276 conditions. Of these, 159 were in favour of screening, 98 were against and no suggestion was made either way in 19.
Want to read more?
Unlock full access to RCNi Plus today
Save over 50% on your first three months:
- Customisable clinical dashboard featuring 200+ topics
- Unlimited online access to all 10 RCNi Journals including Nursing Children and Young People
- RCNi Learning featuring 180+ RCN accredited learning modules
- NMC-compliant RCNi Portfolio to build evidence for revalidation
- Personalised newsletters tailored to your interests